Skip to main content
. Author manuscript; available in PMC: 2017 Feb 1.
Published in final edited form as: Cancer Immunol Res. 2015 Dec 15;4(2):95–100. doi: 10.1158/2326-6066.CIR-14-0126

Figure 1. Tumor protection induced by therapeutic PLG vaccination in combination with blockade antibodies.

Figure 1

(A) A comparison of the tumor growth of untreated mice (Control) bearing established melanoma tumors (inoculated with 5×105 B16-F10 cells and allowed to develop for 9 days) and mice treated after tumor challenge with PLG vaccines (V) or PLG vaccines in combination with antibodies to PD-1 (V+P) or CTLA-4 (V+C). (B) Dot plot of the tumor size in untreated mice (control), and mice treated with PLG vaccines (V) or PLG vaccines in combination with antibodies to PD-1 (V+P) or CTLA-4 (V+C) at 30 days after tumor challenge. (C) A comparison of the survival of untreated mice (Control) and mice treated with PLG vaccines (V) or PLG vaccines in combination with antibodies to PD-1 (V+P) or CTLA-4 (V+C) after tumor challenge. The antibody treatments were initiated on day 3 and injected i.p. every 3 days for 30 days after tumor challenge. Values in A (n=24) represent mean and SEM. ** P<0.01 as the vaccine compared to other experimental conditions (V vs Control, V vs V+P, V vs V+C) unless otherwise noted. This experiment was performed three times (n=8; N=24 in total) and results were pooled together.